These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15583638)

  • 1. The perils of subsidiarity.
    Nat Biotechnol; 2004 Dec; 22(12):1483. PubMed ID: 15583638
    [No Abstract]   [Full Text] [Related]  

  • 2. A lifeline for the biotech sector.
    Kessel M
    Nat Biotechnol; 2009 Feb; 27(2):123-4. PubMed ID: 19204686
    [No Abstract]   [Full Text] [Related]  

  • 3. Strategic rethink for German biotechnology.
    Fernandes M; Miska D
    Nat Biotechnol; 2002 Oct; 20(10):970-1. PubMed ID: 12355106
    [No Abstract]   [Full Text] [Related]  

  • 4. Obama says more money.
    Tollefson J
    Nature; 2009 Apr; 458(7242):1085. PubMed ID: 19407760
    [No Abstract]   [Full Text] [Related]  

  • 5. Cash-strapped biotechs find financing alternative.
    Mitchell P
    Nat Biotechnol; 2004 Sep; 22(9):1057-8. PubMed ID: 15340452
    [No Abstract]   [Full Text] [Related]  

  • 6. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 7. Sunbaked biotechnology in Australia.
    Littlejohn T
    Nat Biotechnol; 2002 Sep; 20(9):873-7. PubMed ID: 12205502
    [No Abstract]   [Full Text] [Related]  

  • 8. The changing norms of the life sciences.
    Shorett P; Rabinow P; Billings PR
    Nat Biotechnol; 2003 Feb; 21(2):123-5. PubMed ID: 12560827
    [No Abstract]   [Full Text] [Related]  

  • 9. Biotech weathers 2Q12 slump.
    Yang W
    Nat Biotechnol; 2012 Aug; 30(8):738. PubMed ID: 22871704
    [No Abstract]   [Full Text] [Related]  

  • 10. Fundraising 101: why seek private funding?
    Duyck GP
    J Public Health Manag Pract; 2008; 14(2):199-201. PubMed ID: 18287928
    [No Abstract]   [Full Text] [Related]  

  • 11. Defending the public health system.
    Armstrong F
    Aust Nurs J; 2001 Jun; 8(11):18-20. PubMed ID: 11894556
    [No Abstract]   [Full Text] [Related]  

  • 12. Ambitious French biotech plan faces EU hurdle.
    Hodgson J
    Nat Biotechnol; 2003 Feb; 21(2):113-4. PubMed ID: 12560821
    [No Abstract]   [Full Text] [Related]  

  • 13. Public sector seeks to bridge 'valley of death'.
    Moran N
    Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
    [No Abstract]   [Full Text] [Related]  

  • 14. Wrong map: why public science can't really be public.
    Mukherjee S
    New Repub; 2000 May; 222(19):14-5. PubMed ID: 12465651
    [No Abstract]   [Full Text] [Related]  

  • 15. Little science, big bucks.
    DeFrancesco L
    Nat Biotechnol; 2003 Oct; 21(10):1127-9. PubMed ID: 14520387
    [No Abstract]   [Full Text] [Related]  

  • 16. Hong Kong domestic health spending: financial years 1989/90 to 2012/13.
    Tin KY; Song W; Tsoi PK; Lee YH; Chong DS; Lam DW; Yeung AY; Ma ES; Maw CK
    Hong Kong Med J; 2016 Jun; 22(3 Suppl 3):1-24. PubMed ID: 27389870
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotech R&D still reeling.
    Lawrence S
    Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
    [No Abstract]   [Full Text] [Related]  

  • 18. Lack of private financing hobbles emerging biotech regions.
    Jia H; Jayarama KS; Astvatsaturyan M
    Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
    [No Abstract]   [Full Text] [Related]  

  • 19. Marketing biotechnology with a Gallic flair.
    Jouanneau AC
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE36-7. PubMed ID: 12874977
    [No Abstract]   [Full Text] [Related]  

  • 20. Investing in nanotechnology.
    Paull R; Wolfe J; Hébert P; Sinkula M
    Nat Biotechnol; 2003 Oct; 21(10):1144-7. PubMed ID: 14520393
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.